Media stories about Invitae (NYSE:NVTA) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Invitae earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 44.8033263040462 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
Shares of NYSE NVTA traded up $0.22 during mid-day trading on Tuesday, reaching $7.46. The company had a trading volume of 68,666 shares, compared to its average volume of 658,523. The company has a quick ratio of 2.53, a current ratio of 2.53 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $456.99 million, a price-to-earnings ratio of -2.82 and a beta of 1.03. Invitae has a 1-year low of $4.35 and a 1-year high of $10.41.
Invitae (NYSE:NVTA) last issued its earnings results on Wednesday, May 9th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.05). The company had revenue of $27.67 million during the quarter, compared to analyst estimates of $26.86 million. Invitae had a negative return on equity of 127.38% and a negative net margin of 154.96%. The business’s revenue was up 167.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. analysts anticipate that Invitae will post -2.22 earnings per share for the current year.
Several equities analysts have recently issued reports on NVTA shares. ValuEngine cut Invitae from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Benchmark decreased their target price on Invitae from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, February 13th. JPMorgan Chase decreased their target price on Invitae from $13.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, February 13th. Finally, Zacks Investment Research cut Invitae from a “hold” rating to a “sell” rating in a report on Wednesday, April 11th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $10.05.
In other Invitae news, insider Randal W. Scott bought 44,444 shares of the firm’s stock in a transaction dated Monday, April 2nd. The stock was acquired at an average price of $4.50 per share, with a total value of $199,998.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shelly D. Guyer sold 5,135 shares of the firm’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $6.96, for a total value of $35,739.60. Following the completion of the sale, the chief financial officer now directly owns 39,865 shares of the company’s stock, valued at approximately $277,460.40. The disclosure for this sale can be found here. Insiders sold a total of 40,515 shares of company stock worth $281,984 over the last 90 days. Insiders own 8.70% of the company’s stock.
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.